BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).

Yuxian Bai,Shukui Qin,Jin Li,Lu Wen,Junsheng Wang,Wenying Deng,Guifang Zhang,Tongfu Jia,Yi Ba,Jianwei. Yang,Xiaoyan Lin,Yifu He,Zhong Xie,Tienan Yi,Xiang Yuan Wu,Feng Ye,Likun Liu,Yong Huang,Mei Wang,Haijun Zhong

BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).

2018

Yuxian Bai
Shukui Qin
Jin Li
Lu Wen
Junsheng Wang
Wenying Deng
Guifang Zhang
Tongfu Jia
Yi Ba
Jianwei. Yang
Xiaoyan Lin
Yifu He
Zhong Xie
Tienan Yi
Xiang Yuan Wu
Feng Ye
Likun Liu
Yong Huang
Mei Wang
Haijun Zhong

e16027Background: Studies have shown BMI could affect long-term survival in advanced gastric cancer. In this analysis, based on a large population, we further investigated the effects of BMI on the...

Keywords:

Pathology
Metastatic gastric cancer
Apatinib
Oncology
Medicine
Internal medicine
in patient
large population
advanced gastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations